Lowey Dannenberg Investigates Fulgent Genetics
Analysis based on 8 articles · First reported Mar 12, 2026 · Last updated Mar 16, 2026
The market is likely to react negatively to Fulgent Genetics due to the investigation, potentially leading to a decline in its stock price. This event highlights the importance of accurate financial reporting and investor protection in the broader market.
Lowey Dannenberg P.C. has launched an investigation into Fulgent Genetics, Inc. for potential violations of federal securities laws. This follows Fulgent Genetics' announcement of its fourth quarter and full year 2025 financial results on February 27, 2026, where the company reported full-year revenue of approximately $322.7 million, falling short of its updated guidance. Additionally, fourth-quarter revenue declined sequentially. The law firm is seeking investors who suffered losses in Fulgent Genetics securities to participate in the investigation, with attorneys Andrea Farah and Vincent R. Cappucci Jr. listed as contacts.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard